allogenic myogenic cell therapy (MYOS/Boston Children's Hospital)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameallogenic myogenic cell therapy (MYOS/Boston Children's Hospital)
Drug Alias Nameex vivo dystrophin gene-transduced allogenic stem cell therapy (MYOS/Boston Children's Hospital)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Myogenic potential stem cell therapy
Mechanisms of ActionDystrophin expression stimulants
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMyos Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Children's Hospital CorpMyos Corp
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A